Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-02

Clinical Trial Update: Study of Investigational Drug in Osteoporosis (MK-0217-908) [Phase 3]

View source ↗

Summary

Phase 3 trial update for investigational drug MK-0217-908 in postmenopausal osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-0217-908

Snippet

Sponsor: Organon and Co | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED